Skip to content

Effect of Synbiotic Supplementation on schizophrenia symptoms

Effect of Synbiotic Supplementation on Symptoms and Brain-derived neurotrophic factor (BDNF) in patients with Schizophrenia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20090901002394N46
Enrollment
70
Registered
2019-12-27
Start date
2019-11-27
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: 2 capsules of 500mg Lactocare daily for 8weeks. Intervention 2: Control group: Take 2 placebo capsules daily for 8 weeks.

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Willingness to collaborate Complete the informed consent form by the patient and the patient's guardian Age range 18-65 years Schizophrenia according to DSM-V criteria (By a psychiatrist) Patients with PANSS total score = 50 Outpatient Duration of illness less than 6 years BMI = 23

Exclusion criteria

Exclusion criteria: Pregnancy and lactation A history of drug or alcohol dependence or abuse Diagnosis of mental retardation Diagnosis of major gastrointestinal, renal, heart, cancer, HIV infection ,neurological disease or other immunodeficiency problems Having suicidal or homicidal thoughts Sensitivity to probiotics, prebiotic and synbiotic Change the Dose and type of medication used during the last 2 months Receive of Antibiotics in the last month Consumption of probiotics, prebiotic or synbiotic over the last month Consumption of dietary supplements in the last month

Design outcomes

Primary

MeasureTime frame
Symptoms of schizophrenia. Timepoint: at baseline, and after 2 month. Method of measurement: PANSS scale.;Brain-derived neurotrophic factor. Timepoint: at baseline, and after 2 month. Method of measurement: Eliza.

Secondary

MeasureTime frame
Anxiety and Depression Function. Timepoint: at baseline, and after 2 month. Method of measurement: Hospital Anxiety and Depression Scale.;Gastrointestinal symptoms. Timepoint: at baseline, and after 2 month. Method of measurement: GSRS Scale.;Physical activity. Timepoint: beginning and end of intervention. Method of measurement: IPAQ questionnaire.;Energy intake. Timepoint: beginning and end of intervention. Method of measurement: 24-hour food recall questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Jamali paghaleh

Iran University of Medical Sciences

ccssoommaa@gmail.com+98 21 8670 4805

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026